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Abstract
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leu-
kemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinu-
ation have previously been limited to higher-risk populations with relapsed/refractory
(R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated
patients based on prior lines of therapy, including after ibrutinib discontinuation. Data
were analyzed from two multicenter phase 3 studies of single-agent ibrutinib: RESO-
NATE (PCYC-1112) in patients with R/R CLL and RESONATE-2 (PCYC-1115) in patients
with treatment-naive (TN) CLL without del(17p). This integrated analysis included
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271 ibrutinib-treated non-del(17p) patients with CLL (136 TN and 135 R/R). Median
progression-free survival (PFS) was not reached for subgroups with 0 and 1/2 prior thera-
pies but was 40.6 months for patients with ≥3 therapies (median follow-up: TN,
36 months; R/R, 44 months). Median overall survival (OS) was not reached in any sub-
group. Overall response rate (ORR) was 92% in TN and 92% in R/R, with depth of
response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to
AEs were similar between patient groups. Most patients (64%) remain on treatment. OS
following discontinuation was 9.3 months in R/R patients (median follow-up 18 months,
n = 51) and was not reached in TN patients (median follow-up 10 months, n = 30). In this
integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR
regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib
discontinuation were for patients receiving ibrutinib in earlier lines of therapy.
1 | INTRODUCTION
The B-cell receptor (BCR) signaling pathway has emerged as an
important therapeutic target for B-cell malignancies, including chronic
lymphocytic leukemia (CLL).1 Bruton's tyrosine kinase (BTK), a com-
ponent of signaling via the BCR, plays a role in the survival, prolifera-
tion, tissue adhesion, and migration of CLL cells.1–5 Ibrutinib, a first-
in-class, once-daily oral BTK inhibitor, is indicated by the United
States Food and Drug Administration and the European Medicines
Agency for treating patients with CLL, including del(17p) CLL, and
allows for treatment without chemotherapy. Results from the phase
3 RESONATE-2 study (PCYC-1115) of ibrutinib versus chlorambucil
in treatment-naive (TN) patients with CLL showed significantly pro-
longed progression-free survival (PFS) and overall survival (OS) with
ibrutinib.6 In patients with relapsed/refractory (R/R) CLL, the phase
3 RESONATE study (PCYC-1112) of ibrutinib versus ofatumumab
showed superior PFS and OS with ibrutinib.7 Data from RESONATE
suggest that outcomes with ibrutinib in the relapsed setting vary by
extent of prior therapy; patients treated with ibrutinib after one prior reg-
imen experience significantly longer PFS than patients treated in later
lines.8 As BCR signaling inhibitors are only recently available for CLL, and
patients discontinue infrequently, few studies have evaluated patient
outcomes following cessation of ibrutinib. Recent institutional analyses
that included high-risk, multiply relapsed patients reported poor survival
in those who discontinued ibrutinib.9,10 We conducted an integrated
analysis of two phase 3 studies to evaluate outcomes with ibrutinib in
CLL based on the number of prior lines of therapy, including after ibruti-
nib discontinuation.
2 | PATIENTS AND METHODS
2.1 | Patients, treatment regimen, and clinical end
points
Data were analyzed from patients from two multicenter, randomized
phase 3 studies of single-agent ibrutinib: RESONATE-2 (NCT01722487)
in TN patients ≥65 years of age6 and RESONATE (NCT01578707)
in patients with CLL treated with ≥1 prior therapy, as previously
described.6,7 RESONATE-2 excluded patients with del(17p); there-
fore, this subgroup was also excluded from RESONATE for this
analysis to ensure a homogeneous dataset. Patients treated with
1 to 2 prior lines of therapy were combined because the number of
patients treated with one prior therapy was small (n = 27).
In both studies, patients on the ibrutinib arm received ibruti-
nib 420 mg once daily continuously. Patients on the comparator
arm received up to 12 cycles of chlorambucil (RESONATE-2)
or 24 weeks of intravenous ofatumumab (RESONATE), and
those patients with progression confirmed by an Independent
Review Committee were allowed to cross over to ibrutinib.6,7
Details regarding drug administration have been previously
published.6,7
Clinical end points included PFS, OS, overall response rate (ORR),
and safety (grading of severity of adverse events [AEs] based on
CTCAE 4.0). In addition, OS post-discontinuation of ibrutinib and
comparator treatments were assessed. PFS and ORR were based on
investigator assessment.
Studies were approved by the institutional review boards at each
participating institution and conducted in accordance with the Decla-
ration of Helsinki. All patients provided written informed consent.
RESONATE and RESONATE-2 were registered at www.clinicaltrials.
gov as NCT01578707 and NCT01722487.
2.2 | Statistical considerations
Patient subgroups were defined according to the number of lines of
therapy received before ibrutinib (0, 1-2, ≥3 prior lines). Descriptive
analysis was used to summarize demographics, baseline characteris-
tics, and safety. OS post-discontinuation was measured from the date
of ibrutinib discontinuation to the date of last follow-up or death.
Time-to-event end points were estimated using the Kaplan-Meier
method.
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3 | RESULTS
3.1 | Patients
This integrated analysis included 271 ibrutinib-treated patients: 136 from
RESONATE-2 and 135 from RESONATE (1-2 prior, 68; ≥3 prior, 67).
TN patients were older and had a lower frequency of high-risk genomic
abnormalities, such as del(11q) and complex karyotype relative to the
R/R group (Supporting Information Table 1).
3.2 | Efficacy
Median follow-up was 36 months for TN patients and 44 months for
R/R patients (44 mo with 1-2 prior; 44 mo with ≥3 prior). Median PFS
was not reached for patients with 0 and 1-2 prior therapies, and was
40.6 months in patients with ≥3 prior therapies (Figure 1). The differ-
ences in PFS between 0 versus ≥3 lines of therapy and 1-2 versus ≥3
lines of therapy were significant (P < 0.0001 and P = 0.0109, respec-
tively); the difference in PFS between 0 versus 1-2 lines of therapy
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F IGURE 1 Progression-free
survival and overall survival with
ibrutinib by prior lines of therapy.
A, Progression-free survival by
investigator assessment. B, Overall
survival. Median follow-up times by
subgroups were 36 months for
0 prior and 44 months for 1/2 prior
and ≥3 prior. The tick marks indicate
patients with censored data. NE, not
estimable; NR, not reached; OS,
overall survival; PFS, progression-
free survival
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was not significant (P = 0.2387). The 36-month PFS rate for each
group was 81%, 74%, and 54%, respectively. In patients with del(11q),
median PFS was 38.5 months for patients with ≥3 prior therapies, and
was not reached for patients with 0 to 2 prior therapies (data not
shown). Median OS was not reached in any subgroup. The difference
in OS between 0 versus ≥3 lines of therapy was significant
(P = 0.0091); differences in OS between 0 versus 1-2 lines of therapy
and 1-2 versus ≥3 lines of therapy were not significant (P = 0.2349 and
P = 0.2375, respectively). The 36-month OS rate was 88%, 83%, and
75% for patients with 0, 1-2, or ≥3 prior therapies, respectively.
The ORR was 92% (complete response [CR], 22%) in TN patients
and 92% (CR, 7%) across previously treated subgroups (96% [CR, 6%]
for 1-2 prior treatments and 88% [CR, 7%] for ≥3 prior therapies).
Analysis of cumulative response over time showed that response
rates (including CRs) increased regardless of lines of therapy
(Figure 2), particularly in those who received ibrutinib as their initial
treatment. The median time to CR was 20 months (range, 7-38) for
TN patients, 10 months (range, 6-14) for patients with 1-2 prior lines,
and 17.5 months (range, 5-36) for patients with ≥3 prior lines of
therapy.
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Most patients with baseline anemia (hemoglobin ≤11 g/dL) or
baseline thrombocytopenia (platelet count ≤100 × 109/L) experi-
enced sustained improvement, regardless of previous lines of therapy
(Supporting Information Table 2).
3.3 | Concomitant hematologic support measures
Patients received hematologic support, including growth factors,
transfusions, and intravenous immunoglobulin (IVIG) (Supporting
Information Table 3). Rates of neutrophil growth factor use were
10% in the TN subgroup, 28% in patients with 1-2 prior therapies,
and 24% in the ≥3 prior therapies subgroup. Rates of IVIG use were
5% in patients with 0 prior therapies, 24% in the 1-2 prior therapies
subgroup, and 51% in the ≥3 prior therapies subgroup. Red blood
cell and platelet transfusions were also more frequent among
patients treated with ibrutinib in later lines (Supporting Information
Table 3).
3.4 | Safety
The rate of common AEs by number of prior lines of therapy is shown
in the Supplement for all grade AEs and for ≥3 AEs (Supporting Infor-
mation Tables 4 and 5). The frequency of AEs generally decreased
with time, with AEs in the second and subsequent years of ibrutinib
therapy occurring less frequently relative to the first year (Figure 3).
Hypertension of any grade occurred more frequently after the first
year (8% during first year, 15% in year 2, 20% in year 3, and 19% in
years >3) in previously treated patients; more frequent grade ≥3
hypertension events also occurred after the first year (Figure 3B).
Fatal AEs occurred in 11 (8%) TN patients and 11 (8%) R/R patients
over the 37 months of follow-up. Fatal AEs included subdural hema-
toma (n = 1), infections or infectious complications (n = 7), other neo-
plasms including Richter's transformation (n = 4), myocardial infarction
(n = 2), small intestinal obstruction (n = 1), pulmonary fibrosis (n = 1),
and other/not specified (n = 6).
3.5 | Treatment exposure and discontinuation
Median duration of ibrutinib treatment was 36 months (range,
1-43), 43 months (range, 1-50), and 39 months (range, 1-50) in
patients with 0, 1-2, and ≥3 prior treatments, respectively, and the
majority of patients continued on ibrutinib (Supporting Information
Table 6).
The overall rate of ibrutinib discontinuation was 36%. The main
reason for discontinuation was progressive disease (PD) for R/R
patients, and was AEs for TN patients (Supporting Information
Figure 1). Discontinuation due to Richter's transformation was higher
in R/R compared to TN patients. Discontinuation due to AEs was
similar for TN and R/R patients and decreased for all patients as
treatment duration increased (Supporting Information Table 6). The
most common AEs leading to discontinuation (listed as TN or R/R)
were infections (4%/5%); malignant, benign, or unspecified neo-
plasms (2%/5%); nervous system disorders (3%/1%); cardiac
disorders (3%/2%); and blood and lymphatic system disorders
(1%/2%). The most common AEs leading to dose reductions (in >2
patients) included neutropenia (n = 5; 2%), atrial fibrillation (n = 4;
1%), and anemia, thrombocytopenia, diarrhea, and arthralgia (n = 3;
1% each). Overall, discontinuation due to PD occurred in 32 of
271 patients (12%), including five TN patients (4%; one patient had
Richter's transformation) and 27 R/R patients (20%; six patients had
Richter's transformation), and occurred less frequently in patients
treated with ibrutinib in earlier lines of therapy (Supporting Informa-
tion Table 6).
3.6 | Outcomes following ibrutinib discontinuation
Data from 30 TN and 52 R/R patients were evaluated for outcomes
following ibrutinib discontinuation (Table 1). The median OS following
discontinuation was not reached for TN patients (n = 30), 9.3 months
for patients with 1-2 prior therapies (n = 22), and 8.9 months for
patients with ≥3 prior therapies (n = 30) at median follow-ups of
10, 15, and 18 months, respectively.
For comparison, 117 patients on the comparator arms were eval-
uated for outcomes following discontinuation of chlorambucil for TN
patients and ofatumumab for the R/R subgroup. Median OS follow-
ing discontinuation was 30.7 months for TN patients, 8 months for
patients treated with ≥3 prior therapies, and was not reached in
patients with 1-2 prior therapies (Supporting Information Table 7).
When 52 patients who received ibrutinib after crossover were
excluded, median OS was 29.4 months for TN patients, versus 2.5 to
2.7 months for patients with ≥1 prior therapy (Supporting Informa-
tion Table 7).
Data on subsequent therapy following ibrutinib discontinuation
were available for nine TN patients and 31 R/R patients (Supporting
Information Table 8), with several of these patients receiving multiple
subsequent therapies. Data on best responses to the first subsequent
therapy after ibrutinib were available for seven TN patients (six PRs
following chemotherapy, or chemoimmunotherapy and one SD fol-
lowing radiation therapy).
Patients given ibrutinib as second-line or third-line therapy,
subsequently received chemoimmunotherapy regimens including
rituximab with cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP), modified R-CHOP, and rituximab, etoposide,
prednisone, vincristine, cyclophosphamide, and doxorubicin (R-
EPOCH), as well as a range of newer therapies, including idelalisib
(with or without rituximab) and venetoclax. Patients given ibrutinib
in the fourth line or beyond were subsequently treated with
cyclophosphamide-prednisone chemotherapy; novel therapies,
such as BTK inhibitors; or investigational agents under clinical
development. For R/R patients, data on best responses to the first
subsequent therapy after ibrutinib were available for 26 patients:
three CRs, three PRs, and eight SDs were observed, with the other
12 patients having PD. The patients achieving CR received an
investigational agent, EPOCH-R, or doxorubicin, vinblastine, dacar-
bazine ± bleomycin (AVD ± B); patients with a PR received ofatu-
mumab, cyclophosphamide, doxorubicin, and vincristine (R-CHO),
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or venetoclax. The eight patients who had SD received either an
anti-CD20 monoclonal antibody-based therapy (n = 4), EPOCH
(n = 1), or an anti-CD52 monoclonal antibody-based regimen (n = 3).
The 12 patients who progressed had subsequent therapies that
included anti-CD20 monoclonal antibodies, anti-CD52 monoclonal anti-
bodies, PI3K inhibitors, or chemotherapy-based regimens.
4 | DISCUSSION
This integrated analysis of two phase 3 studies supports the utilization
of ibrutinib as the choice for first-line therapy and also demonstrates
that treatment with ibrutinib does not impair the ability to utilize
other active therapies including chemoimmunotherapy or venetoclax,
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as subsequent lines of therapy. With a median follow-up of 36 and
44 months for TN and R/R subgroups, respectively, median PFS was
not reached for patients with 0 and 1-2 prior lines of therapy and was
41 months for those with ≥3 prior lines. Median OS was not reached
regardless of number of prior lines of therapy. The ORR was high
(88%-96%) for all subgroups with highest CR rates for TN patients,
and the proportion of CRs increasing over time. Independent of the
number of prior treatments, ibrutinib resulted in sustained improve-
ments in hematologic parameters in most patients with baseline ane-
mia or thrombocytopenia.
AEs with ibrutinib were largely grade 1 to 2, and the safety profile
was similar for the TN and R/R subgroups; however, the frequency
of AEs differed. For example, grade ≥3 infections and cytopenias
occurred less frequently among TN patients compared with R/R
patients. These results are consistent with long-term follow-up ana-
lyses of phase 2 studies of ibrutinib in CLL,11,12 and are further sup-
ported by the infrequent use of growth factors, IVIG, and transfusions
among TN patients in this analysis. We also observed that the fre-
quency of most AEs decreased over time. Grade ≥ 3 hypertension
occurred more frequently after the first year of ibrutinib among previ-
ously treated patients. Although an increase in the prevalence of
hypertension would be expected over time in any aging population,
the frequency of hypertension was found to be higher with ibrutinib
than in the comparator arm in RESONATE-2.6 Patients in this analysis
received ibrutinib for longer durations on average than patients
receiving comparator drugs; this may partially explain the higher prev-
alence of hypertension in the ibrutinib arm.
Discontinuation of ibrutinib due to AEs occurred at a similar rate
in the TN patients and R/R subgroups without a specific AE markedly
predominant; however, the rate of discontinuations due to AEs among
real-world patients in a retrospective analysis was higher.13 Discontin-
uation due to PD occurred in 12% of patients, similar to the rate of
progression-related ibrutinib discontinuation previously reported
(10%-12%).9,10 Patients treated with ibrutinib in earlier lines also
tended to have lower rates of progression and experienced better
PFS and OS outcomes relative to more heavily treated patients. The
risk of progression on ibrutinib has previously been reported to
increase with high-risk factors like del(17p), unmutated IGHV, complex
karyotype, or BCL6 abnormalities.9,10 In our analysis, TN patients
tended to have a lower frequency of unmutated IGHV and complex
karyotype than patients with R/R disease; data from patients with del
(17p) were excluded from our study to more accurately compare the
study population in the RESONATE-2 study. Thus, this analysis can-
not evaluate the impact of these higher risk markers.
Among previously treated patients, those receiving ibrutinib in
earlier (1-2 prior) lines of therapy experienced better survival out-
comes compared with those receiving ibrutinib in later (≥3 prior) lines
of therapy. There was a significant difference in PFS between patients
who received 0 versus ≥3 lines of therapy and 1-2 versus ≥3 lines of
therapy; the difference in PFS between patients receiving 0 versus
1-2 lines of therapy was not significant. These findings are consistent
with the results of an integrated analysis of three randomized studies,
which included 620 ibrutinib-treated patients of whom 136 were
TN and 66 had received one prior therapy.14 Multivariate analyses
showed that patients with one prior therapy had better PFS than
patients treated with ibrutinib in later lines. Patients with 0 prior ther-
apies demonstrated longer survival compared with patients with ≥3
prior lines of therapy. This observation is true of most therapies for
CLL, and the effect of more prior therapies may be less with ibrutinib
than with other therapies. There was no significant difference in OS
between patients who received 0 versus 1-2 or 1-2 versus 3 lines of
therapy. This suggests that patients who have PD on first-line therapy
may be able to receive ibrutinib therapy as second-line therapy with-
out any adverse consequences.
Moreover, survival following ibrutinib discontinuation was compa-
rable with survival following discontinuation of other single-agent
therapies, as shown in our analysis of OS outcomes in the comparator
arms. Although patient numbers are small, those treated after ≥3 prior
lines of therapy who discontinued ofatumumab and did not cross over
to ibrutinib appeared to have the poorest outcomes with median OS
of <3 months.
Analyses of ibrutinib-treated CLL patients reported poor survival
following discontinuation of ibrutinib.9,10 One single-institution study
reported poor salvageability of 33 patients treated with regimens
including chemoimmunotherapy or ofatumumab following ibrutinib
discontinuation.9 Another study of pooled data from 308 patients
treated with ibrutinib in four clinical studies confirmed the poor prog-
nosis of patients after discontinuation of ibrutinib.10 These analyses
also revealed that patients who discontinued because of PD with
transformation (Richter's or other) had dismal outcomes with median
OS of 2.6 to 3.5 months post-ibrutinib discontinuation.9,10 In con-
trast, median OS ranged from 17.6 months to not reached among
TABLE 1 Summary of outcomes following ibrutinib discontinuation
Subgroups by prior lines of therapy
0 (n = 30) 1/2 (n = 22) ≥3 (n = 30)
Median follow-up, months 10 15 18
Median OS,a months (95% CI) NR (5.9-NE) 9.3 (7.8-22) 8.9 (4.3-NE)
Median OS post-DC due to PD, months 22.7 (0.6-22.7) [n = 5] 8.7 (0.5-16) [n = 8] 8.9 (2.8-NE) [n = 19]
Median OS post-DC due to AE, months NR (5.9-NE) [n = 22] 15.5 (6.9-22) [n = 9] NR (2.6-NE) [n = 7]
Abbreviations: AE, adverse event; DC, discontinuation; NE, not estimable; NR, not reached; OS, overall survival; PD, progressive disease.
aSix patients who discontinued study ibrutinib to receive commercial ibrutinib are not included.
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patients who discontinued because of PD without transformation.10
Initial reports from these studies indicated that patients who discon-
tinued because of nonrelapse reasons (including AEs) also had a poor
prognosis following ibrutinib discontinuation.9,10 However, these
reports primarily included very high-risk patients with combinations
of del(17p), unmutated IGHV, or complex karyotype, who were exten-
sively pretreated, had relapsed early, and/or had exhausted available
treatments, including anti-CD20 therapies, alkylating agents, and
purine analogs.9,10 In addition, few TN patients were included, and
follow-up durations were shorter than in the current study. Subse-
quently, longer follow-up of one study indicated that better survival
outcomes were observed in patients who discontinued because of
treatment-related toxicity compared with progressive CLL.15 Consis-
tent with these updated findings, in the present analysis, patients
who discontinued because of AEs had better survival outcomes than
those who discontinued because of PD, particularly in later lines of
therapy.
The studies described above were conducted before the availabil-
ity of venetoclax or idelalisib; recent studies have shown more favor-
able outcomes when these novel agents were used following
discontinuation of ibrutinib.16–19 A multicenter, retrospective study
that evaluated 178 patients following discontinuation of ibrutinib or
idelalisib (N = 178) reported an ORR of 50% with an alternative kinase
inhibitor, 25% with chemoimmunotherapy, 36% with anti-CD20
monoclonal antibody, and 76% with BCL-2 inhibitor therapy.17 Of the
16 patients who received idelalisib, the ORR was 28%.17 Results from
a phase 2 study of venetoclax showed an ORR of 70% in a subgroup
of 43 patients previously treated with ibrutinib.19 An analysis of
patients receiving frontline ibrutinib showed promising results
wherein patients responded to chemoimmunotherapy regimens and
chlorambucil after discontinuation of ibrutinib.20 In the present analy-
sis, many patients who received therapies following ibrutinib discon-
tinuation remained alive, albeit with short follow-up. Factors such as
number of prior therapies, presence or absence of del(17p), and avail-
ability of subsequent therapies, may contribute to the observed differ-
ences in post-ibrutinib salvageability across these various studies.
Currently, few patients have progressed on treatment with single-
agent ibrutinib. Evolving data from the RESONATE-2 study suggest
responses with chemoimmunotherapy after treatment with ibrutinib
in the first-line setting is achievable.20
This integrated, retrospective analysis of the randomized RESO-
NATE and RESONATE-2 studies supports once-daily treatment with
single-agent ibrutinib leading to high response rates and favorable
survival in patients with CLL/SLL, with the best outcomes experi-
enced in those who receive ibrutinib in earlier lines of therapy.
Further, the analysis suggests that the best outcomes following dis-
continuation of ibrutinib were observed in patients who received
ibrutinib in the first-line or second-/third-line settings. As follow-up
matures, results of outcomes with subsequent anticancer regimens
will allow for a better understanding of salvageability following ibru-
tinib discontinuation, particularly for those who have not received
standard chemoimmunotherapy.
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